Business Context and Reporting Period
The filing is Gemphire Therapeutics Inc.’s unaudited Form 10-Q for the three months ended March 31, 2019. The request metadata identifies Metavia Inc., but the filing itself identifies Gemphire Therapeutics Inc. as the registrant. Gemphire was a clinical-stage biopharmaceutical company developing gemcabene for dyslipidemia, including orphan indications, and NAFLD/NASH. It had no approved products or revenue.
Financial Performance and Position
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $1.4 million | $2.1 million | Down $0.7 million |
| Research and development expense | $1.4 million | $5.0 million | Down $3.6 million |
| Total operating expenses | $2.8 million | $7.1 million | Down $4.3 million |
| Net loss | $3.8 million | $7.2 million | Improved by $3.4 million |
| Net loss per share | $0.27 | $0.58 | Improved |
| Cash used in operating activities | $3.2 million | $7.2 million | Improved by $4.1 million |
| Cash and cash equivalents at period end | $5.5 million | $34.5 million | Prior-year figure includes 2018 offering proceeds |
Because the company had no revenue, conventional revenue or operating profit margins were not meaningful. The operating loss was $2.8 million in Q1 2019, compared with $7.1 million in Q1 2018. Interest expense increased to $0.8 million from $0.2 million, primarily because approximately $0.8 million of unamortized debt discounts were accelerated upon repayment of the term loan. Other expense was $0.2 million, primarily for strategic-alternative transaction costs.
At March 31, 2019, total assets were $6.2 million, total liabilities were $1.7 million, and stockholders’ equity was $4.4 million. The company had $15,000 of restricted cash. Accumulated deficit was $87.9 million.
Material Changes Versus the Prior Comparable Period
- Operating expenses declined substantially because of reduced clinical-trial activity and lower related personnel and professional-service costs.
- Research and development expense fell 72% to $1.4 million, reflecting reduced clinical activity.
- Cash used in operations fell to $3.2 million from $7.2 million.
- The company repaid its Silicon Valley Bank term loan in full on January 28, 2019. Approximately $10.3 million of financing cash outflows represented principal repayment and related amounts.
- Cash and cash equivalents declined from $19.0 million at December 31, 2018 to $5.5 million at March 31, 2019.
- No common shares were issued during Q1 2019; 14,265,411 shares were outstanding at March 31, 2019.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that cash on hand was expected to fund operations into the third quarter of 2019, but additional capital would be required thereafter. The company had no committed external source of funding.
- The financial statements disclose substantial doubt about the company’s ability to continue as a going concern. Management expected to seek equity or debt financing, collaborations, strategic alliances, or licensing arrangements.
- The FDA partial clinical hold prevented human studies of gemcabene exceeding six months. The FDA requested additional preclinical studies, which the company expected to submit in the fourth quarter of 2019. An End-of-Phase 2 meeting was deferred until the hold was lifted.
- The pediatric NAFLD trial was halted early after unexpected increases in liver-related efficacy measures and liver fat in initial patients. The risk of increased liver fat with gemcabene remained unknown.
- A Phase 2a familial partial lipodystrophy study was fully enrolled, with top-line data expected in Q2 2019 according to management.
- The company received a Nasdaq notice for failing to meet the Nasdaq Global Market’s $10 million stockholders’ equity requirement. It submitted an application to transfer its common stock to the Nasdaq Capital Market, which has a $2.5 million equity requirement. Approval and continued compliance were uncertain.
- The company’s common stock had recently traded below Nasdaq’s $1.00 minimum closing bid-price requirement, creating an additional potential delisting risk.
- The Pfizer license required milestone payments of up to $37 million and tiered royalties upon future commercialization. No milestone or royalty liabilities were recorded as of March 31, 2019.
- A 3.5% success fee on the funded principal amount of the former SVB term loan could become payable upon specified future FDA approval, change-of-control, asset-sale, or ownership events through July 24, 2024. No triggering event had occurred or was probable through the filing date.
Most Important Facts for Investors to Verify
- Confirm that the filing applies to Gemphire Therapeutics Inc., not Metavia Inc., as stated in the request metadata.
- Verify the company’s post-quarter-end financing activity and whether it secured sufficient capital to fund operations beyond Q3 2019.
- Verify the status of the FDA partial clinical hold, requested preclinical studies, and any impact on Phase 3 development.
- Verify results from the familial partial lipodystrophy trial and any further safety findings from the halted pediatric NAFLD trial.
- Verify Nasdaq’s decision on the proposed transfer to the Nasdaq Capital Market and compliance with minimum bid-price and equity requirements.
- Review potential dilution from 2.8 million outstanding stock options and 1.0 million outstanding warrants, which were excluded from diluted loss per share because they were antidilutive.